Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group
Authors:
- Aysegul OrucAOAysegul Oruc
- Abdullah SumnuASAbdullah Sumnu
- Aydın TurkmenATAydın Turkmen
- Taner BasturkTBTaner Basturk
- Egemen CebeciECEgemen Cebeci
- Kenan TurgutalpKTKenan Turgutalp
- Hakkı CetinkayaHCHakkı Cetinkaya
- Nurhan SeyahiNSNurhan Seyahi
- Erhan TatarETErhan Tatar
- Metin ErgulMEMetin Ergul
- Ülver DericiÜDÜlver Derici
Open Access
- 18 April 2024
- journal article
- research article
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2341787
Abstract
Immunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate IST results among IgAN patients in Turkiye. The data of 1656 IgAN patients in the Primary Glomerular Diseases Study of the Turkish Society of Nephrology Glomerular Diseases Study Group were analyzed. A total of 408 primary IgAN patients treated with IST (65.4% male, mean age 38.4 ± 12.5 years, follow-up 30 (3-218) months) were included and divided into two groups according to treatment protocols (isolated corticosteroid [CS] 70.6% and combined IST 29.4%). Treatment responses, associated factors were analyzed. Remission (66.7% partial, 33.7% complete) was achieved in 74.7% of patients. Baseline systolic blood pressure, mean arterial pressure, and proteinuria levels were lower in responsives. Remission was achieved at significantly higher rates in the CS group (78% vs. 66.7%, p = 0.016). Partial remission was the prominent remission type. The remission rate was significantly higher among patients with segmental sclerosis compared to those without (60.4% vs. 49%, p = 0.047). In the multivariate analysis, MEST-C S1 (HR 1.43, 95% CI 1.08-1.89, p = 0.013), MEST-C T1 (HR 0.68, 95% CI 0.51-0.91, p = 0.008) and combined IST (HR 0.66, 95% CI 0.49-0.91, p = 0.009) were found to be significant regarding remission. CS can significantly improve remission in high-risk Turkish IgAN patients, despite the reliance on non-quantitative endpoints for favorable renal outcomes. Key predictors of remission include baseline proteinuria and specific histological markers. It is crucial to carefully weigh the risks and benefits of immunosuppressive therapy for these patients.Keywords
This publication has 26 references indexed in Scilit:
- Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA NephropathyJAMA, 2017
- Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled TrialAmerican Journal of Kidney Diseases, 2017
- Intensive Supportive Care plus Immunosuppression in IgA NephropathyNew England Journal of Medicine, 2015
- New Insights into the Pathogenesis of IgA NephropathyKidney Diseases, 2015
- IgA NephropathyNew England Journal of Medicine, 2013
- Corticosteroid Therapy in IgA NephropathyJournal of the American Society of Nephrology, 2012
- Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathyNephrology Dialysis Transplantation, 2009
- Combination Therapy of Prednisone and ACE Inhibitor Versus ACE-Inhibitor Therapy Alone in Patients With IgA Nephropathy: A Randomized Controlled TrialAmerican Journal of Kidney Diseases, 2009
- Factors predicting progression of IgA nephropathiesJournal Of Nephrology, 2005
- Corticosteroid Effectiveness in IgA NephropathyJournal of the American Society of Nephrology, 2004